Ignite Creation Date:
2024-05-06 @ 8:14 PM
Last Modification Date:
2024-10-26 @ 3:23 PM
Study NCT ID:
NCT06304636
Status:
RECRUITING
Last Update Posted:
2024-06-13
First Post:
2024-02-28
Brief Title:
Descartes-15 for Patients With RelapsedRefractory Multiple Myeloma
Sponsor:
Cartesian Therapeutics
Organization:
Cartesian Therapeutics
Study Overview
Official Title:
Descartes-15 for Patients With RelapsedRefractory Multiple Myeloma
Status:
RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
DC15-MM-01
Brief Summary:
This is a Phase I dose-escalation study to evaluate the safety tolerability and preliminary efficacy of an autologous BCMA-targeting RNA-engineered CAR T-cell therapy in patients with RelapsedRefractory Multiple Myeloma The cell product is referred to as Descartes-15
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None